<p>Abivax（纳斯达克股票代码：ABVX - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的研究分析师从 “卖出” 评级上调至 “持有” 评级。</p>
<p>其他几家研究公司也最近对 ABVX 发表了评论。花旗集团在 1 月 8 日（星期四）发布的研究报告中重申了对 Abivax 股票的 “市场跑赢大盘” 评级。摩根士丹利在 1 月 9 日（星期五）的研究报告中将 Abivax 的目标价格从 101.00 美元上调至 145.00 美元，并给予该股票 “增持” 评级。Oppenheimer 在 1 月 8 日（星期四）的报告中设定了 Abivax 的目标价格为 131.00 美元。杰富瑞金融集团在 3 月 16 日（星期一）开始对 Abivax 股票进行覆盖，设定了 “买入” 评级和 160.00 美元的价格目标。最后，Weiss Ratings 在 1 月 21 日（星期三）的报告中重申了对 Abivax 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “强烈买入” 评级，十三位分析师给予 “买入” 评级，一位分析师对该公司的股票给予 “卖出” 评级。根据 MarketBeat.com 的数据，Abivax 的共识评级为 “适度买入”，平均目标价格为 137.15 美元。</p>
<p><strong>查看我们最新的 Abivax 股票报告</strong></p>
<h2>Abivax 股票下跌 1.9%</h2>
<p>纳斯达克：ABVX 的股票在周五以 120.16 美元开盘。该公司的 50 日移动平均价格为 119.10 美元，200 日移动平均价格为 114.65 美元。该公司的市值为 95.3 亿美元，市盈率为-22.38，贝塔值为 1.68。Abivax 的 52 周最低价为 5.59 美元，52 周最高价为 148.83 美元。</p>
<p>Abivax（纳斯达克：ABVX - 获取免费报告）最后一次公布季度财报是在 2 月 14 日（星期六）。该公司报告本季度每股收益为（1.20 美元）。该业务本季度的收入为 52 万美元。作为一个整体，股票分析师预计 Abivax 在当前年度将发布-2.83 的每股收益。</p>
<h2>对 Abivax 的对冲基金看法</h2>
<p>几家对冲基金最近修改了对 ABVX 的持股。WPG Advisers LLC 在第四季度将其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 现在拥有 454 股该公司的股票，价值 61,000 美元，在此期间又购买了 253 股。凯通国际资产管理有限公司在第四季度将其在 Abivax 的持股增加了 661.5%。凯通国际资产管理有限公司现在拥有 396 股该公司的股票，价值 53,000 美元，在此期间又收购了 344 股。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 现在拥有 377 股该公司的股票，价值 32,000 美元，在此期间又收购了 369 股。First Horizon Corp 在第三季度购买了 Abivax 的新股份，价值约 36,000 美元。最后，夏威夷银行在第四季度将其在 Abivax 的持股增加了 14.9%。夏威夷银行现在拥有 3,454 股该公司的股票，价值 466,000 美元，在上个季度又收购了 448 股。目前 47.91% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Abivax</h2>
<p>（获取免费报告）</p>
<p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发针对慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供一种旨在疾病修饰和改善安全性特征的差异化方法。</p>
<p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Abivax 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
<p>在你考虑 Abivax 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Abivax 并不在名单上。</p>
<p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABVX

<p>华尔街禅将 Abivax (NASDAQ:ABVX) 的评级从 “卖出” 上调至 “持有”。其他公司如花旗集团和摩根士丹利也给予了积极的评级，其中摩根士丹利将目标价上调至 145 美元。Abivax 的股票目前下跌 1.9%，交易价格为 120.16 美元，市值为 95.3 亿美元。该公司报告的季度每股收益为（1.20 美元），预计本年度每股收益为-2.83 美元。机构投资者持有该股票的 47.91%</p>

<p>Abivax (NASDAQ:ABVX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Abivax（纳斯达克股票代码：ABVX - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的研究分析师从 “卖出” 评级上调至 “持有” 评级。</p>
</div><p>Several other research firms have also recently commented on ABVX. Citigroup restated a &#34;market outperform&#34; rating on shares of Abivax in a research report on Thursday, January 8th. Morgan Stanley boosted their price target on Abivax from $101.00 to $145.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, January 9th. Oppenheimer set a $131.00 price target on Abivax in a report on Thursday, January 8th. Jefferies Financial Group started coverage on shares of Abivax in a research note on Monday, March 16th. They set a &#34;buy&#34; rating and a $160.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Abivax has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.15.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 ABVX 发表了评论。花旗集团在 1 月 8 日（星期四）发布的研究报告中重申了对 Abivax 股票的 “市场跑赢大盘” 评级。摩根士丹利在 1 月 9 日（星期五）的研究报告中将 Abivax 的目标价格从 101.00 美元上调至 145.00 美元，并给予该股票 “增持” 评级。Oppenheimer 在 1 月 8 日（星期四）的报告中设定了 Abivax 的目标价格为 131.00 美元。杰富瑞金融集团在 3 月 16 日（星期一）开始对 Abivax 股票进行覆盖，设定了 “买入” 评级和 160.00 美元的价格目标。最后，Weiss Ratings 在 1 月 21 日（星期三）的报告中重申了对 Abivax 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “强烈买入” 评级，十三位分析师给予 “买入” 评级，一位分析师对该公司的股票给予 “卖出” 评级。根据 MarketBeat.com 的数据，Abivax 的共识评级为 “适度买入”，平均目标价格为 137.15 美元。</p>
</div><p><strong>View Our Latest Stock Report on Abivax</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Abivax 股票报告</strong></p>
</div><h2>Abivax Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Abivax 股票下跌 1.9%</h2>
</div><p>Shares of NASDAQ:ABVX opened at $120.16 on Friday. The company's 50-day moving average price is $119.10 and its 200 day moving average price is $114.65. The company has a market cap of $9.53 billion, a PE ratio of -22.38 and a beta of 1.68. Abivax has a fifty-two week low of $5.59 and a fifty-two week high of $148.83.</p>
<div class="lb-trans"><p>纳斯达克：ABVX 的股票在周五以 120.16 美元开盘。该公司的 50 日移动平均价格为 119.10 美元，200 日移动平均价格为 114.65 美元。该公司的市值为 95.3 亿美元，市盈率为-22.38，贝塔值为 1.68。Abivax 的 52 周最低价为 5.59 美元，52 周最高价为 148.83 美元。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The business had revenue of $0.52 million for the quarter. As a group, equities analysts anticipate that Abivax will post -2.83 EPS for the current year.</p>
<div class="lb-trans"><p>Abivax（纳斯达克：ABVX - 获取免费报告）最后一次公布季度财报是在 2 月 14 日（星期六）。该公司报告本季度每股收益为（1.20 美元）。该业务本季度的收入为 52 万美元。作为一个整体，股票分析师预计 Abivax 在当前年度将发布-2.83 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Abivax</h2>
<div class="lb-trans"><h2>对 Abivax 的对冲基金看法</h2>
</div><p>Several hedge funds have recently modified their holdings of ABVX. WPG Advisers LLC lifted its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after buying an additional 253 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company's stock worth $53,000 after acquiring an additional 344 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after acquiring an additional 369 shares during the period. First Horizon Corp bought a new stake in Abivax in the third quarter worth about $36,000. Finally, Bank of Hawaii raised its position in Abivax by 14.9% in the fourth quarter. Bank of Hawaii now owns 3,454 shares of the company's stock worth $466,000 after acquiring an additional 448 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近修改了对 ABVX 的持股。WPG Advisers LLC 在第四季度将其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 现在拥有 454 股该公司的股票，价值 61,000 美元，在此期间又购买了 253 股。凯通国际资产管理有限公司在第四季度将其在 Abivax 的持股增加了 661.5%。凯通国际资产管理有限公司现在拥有 396 股该公司的股票，价值 53,000 美元，在此期间又收购了 344 股。EverSource Wealth Advisors LLC 在第三季度将其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 现在拥有 377 股该公司的股票，价值 32,000 美元，在此期间又收购了 369 股。First Horizon Corp 在第三季度购买了 Abivax 的新股份，价值约 36,000 美元。最后，夏威夷银行在第四季度将其在 Abivax 的持股增加了 14.9%。夏威夷银行现在拥有 3,454 股该公司的股票，价值 466,000 美元，在上个季度又收购了 448 股。目前 47.91% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Abivax</h2>
<div class="lb-trans"><h2>关于 Abivax</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发针对慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供一种旨在疾病修饰和改善安全性特征的差异化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Abivax 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Abivax 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Abivax 并不在名单上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Abivax (NASDAQ:ABVX) Upgraded to "Hold" at Wall Street Zen

Market Beat

Abivax SA

花旗

摩根士丹利

奥本海默控股

Jefferies Financial

第一地平线

夏威夷银行

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF HAWAII CORPORATION DEP SHS REPSTG 1/40TH INT SH NON CUM PER

BANK OF HAWAII CORP 4.375% DEP SHS REPSTG 1/40TH PFD SER A

Abivax（NASDAQ 代码：ABVX）在 Wall Street Zen 被上调至 “持有” 评级